This article is more than 5 years old. Information may no longer be current.

J&J will market three Santen drugs in United States

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

JACKSONVILLE, Fla. — Johnson & Johnson Vision Care has secured U.S. distribution rights to three ophthalmic drugs from Japan’s Santen Pharmaceuticals, the Florida-based company announced in a press release.

Beginning this quarter, Johnson & Johnson Vision Care will become the U.S. distributor of Quixin (levofloxacin), Betimol (timolol) and Alamast (pemirolast) for Santen. Daiichi Pharmaceuticals is the licensor of levofloxacin. Santen will continue to have responsibility for manufacturing, clinical and regulatory activities associated with the products.

According to a Reuters report, the three drugs totaled $23.3 million in sales for the past fiscal year, which ended in March. Santen chose to turn the marketing operation over to a local company because it had been losing money, according to Reuters.